Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach

1 Van Meir EG, Hadjipanayis CG, Norden AD, Shu H-K, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-93. 10.3322/caac.20069288847420445000Search in Google Scholar

2 Ardebili SY, Zajc I, Gole B, Campos B, Herold-Mende C, Drmota S, et al. CD133/prominin1 is prognostic for GBM patient’s survival, but inversely correlated with cysteine cathepsins’ expression in glioblastoma derived spheroids. Radiol Oncol 2011; 45: 102-15. 10.2478/v10019-011-0015-6342373122933943Search in Google Scholar

3 Kalinina J, Peng J, Ritchie JC, Van Meir EG. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 2011; 13: 926-42. 10.1093/neuonc/nor078315801521852429Search in Google Scholar

4 Martens T, Matschke J, Müller C, Riethdorf S, Balabanov S, Westphal M, et al. Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases. Clin Neurol Neurosurg 2013; 115: 323-8. 10.1016/j.clineuro.2012.05.02522704562Search in Google Scholar

5 Xu BJ, An Q a, Srinivasa Gowda S, Yan W, Pierce L a, Abel TW, et al. Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma. Int J Oncol 2012; 40: 1995-2003. Search in Google Scholar

6 Reynés G, Vila V, Martín M, Parada A, Fleitas T, Reganon E, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011; 102: 35-41. 10.1007/s11060-010-0290-x20607353Search in Google Scholar

7 Gupta MK, Polisetty R V, Ramamoorthy K, Tiwary S, Kaur N, Uppin MS, et al.Search in Google Scholar

Secretome analysis of Glioblastoma cell line - HNGC-2. Mol Biosyst 2013; 9: 1390-400. 10.1039/c3mb25383j23483059Search in Google Scholar

8 Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 2009; 23: 1541-57. 10.1096/fj.08-122184266942619109410Search in Google Scholar

9 Motaln H, Gruden K, Hren M, Schichor C, Primon M, Rotter A, et al. Human mesenchymal stem cells exploit the immune response mediating chemokines to impact the phenotype of glioblastoma. Cell Transplant 2012; 21: 1529-45. 10.3727/096368912X64054722554389Search in Google Scholar

10 Strojnik T, Šmigoc T, Lah T. Neurosurgery Prognostic values of erythrocyte sedimentation rate and C-reactive protein in the blood of glioma patients. Anticancer Res 2014; 34: 339-47. Search in Google Scholar

11 Sato Y, Honda Y, Asoh T, Oizumi K, Ohshima Y, Honda E. Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis. J Neurooncol 1998; 40: 47-50. 10.1023/A:1006078521790Search in Google Scholar

12 Com E, Clavreul A, Lagarrigue M, Michalak S, Menei P, Pineau C. Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. J Proteomics 2012; 75: 3898-913. 10.1016/j.jprot.2012.04.03422575386Search in Google Scholar

13 Fang X, Wang C, Balgley BM, Zhao K, Wang W, He F, et al. Targeted Tissue Proteomic Analysis of Human Astrocytomas. J Proteome Res 2012; 11: 3937-46. 10.1021/pr300303t341326822794670Search in Google Scholar

14 Carlsson A, Persson O, Ingvarsson J, Widegren B, Salford L, Borrebaeck CAK, et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl 2010; 4: 591-602. 10.1002/prca.20090017321137077Search in Google Scholar

15 Gautam P, Nair SC, Gupta MK, Sharma R, Polisetty RV, Uppin MS, et al. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS One 2012; 7: e46153. 10.1371/journal.pone.0046153346102023029420Search in Google Scholar

16 Elstner A, Stockhammer F, Nguyen-Dobinsky T-N, Nguyen QL, Pilgermann I, Gill A, et al. Identification of diagnostic serum protein profiles of glioblastoma patients. J Neurooncology 2011; 102: 71-80. 10.1007/s11060-010-0284-8309456520617365Search in Google Scholar

17 Gollapalli K, Ray S, Srivastava R, Renu D, Singh P, Dhali S, et al. Investigation of serum proteome alterations in human glioblastoma multiforme. Proteomics 2012; 12: 2378-90. 10.1002/pmic.20120000222684992Search in Google Scholar

18 Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3: 367-78. 10.1074/mcp.R400007-MCP20014990683Search in Google Scholar

19 Liu T, Qian W-J, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ, et al. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006; 5: 2167-74. 10.1074/mcp.T600039-MCP200185094416854842Search in Google Scholar

20 Gruden K, Hren M, Herman A, Blejec A, Albrecht T, Selbig J, et al. A “crossomics” study analysing variability of different components in peripheral blood of healthy caucasoid individuals. PLoS One 2012; 7: e28761. 10.1371/journal.pone.0028761325722122253695Search in Google Scholar

21 Bolstad BM, Irizarry R a, Åstrand M, Speed TP, Astrand M. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-93. 10.1093/bioinformatics/19.2.18512538238Search in Google Scholar

22 Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13. 10.1093/nar/gkn923261562919033363Search in Google Scholar

23 Kraus JA, Felsberg J, Tonn JC, Reifenberger G, Pietsch T. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol 2002; 28: 325-33. 10.1046/j.1365-2990.2002.00413.xSearch in Google Scholar

24 Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 2009; 151: 1349-58. 10.1007/s00701-009-0387-1Search in Google Scholar

25 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54. 10.1016/0003-2697(76)90527-3Search in Google Scholar

26 Hamelinck D, Zhou H, Li L, Verweij C, Dillon D, Feng Z, et al. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell proteomics MCP 2005; 4: 773-84. 10.1074/mcp.M400180-MCP20015793073Search in Google Scholar

27 Takenaka K, Kanaho Y, Hara A, Zhang W, Ando T, Sakai N, et al. A guanine nucleotide-binding protein in human astrocytoma. Neurol Res 1990; 12: 223-5. 10.1080/01616412.1990.117399471982164Search in Google Scholar

28 Kirla RM, Haapasalo HK, Kalimo H, Salminen EK. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 2003; 97: 644-8. 10.1002/cncr.1107912548606Search in Google Scholar

29 Huang P, Rani MRS, Ahluwalia MS, Bae E, Prayson RA, Weil RJ, et al. Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin α6β1 in glioblastoma. Cancer Res 2012; 72: 1428-37. 10.1158/0008-5472.CAN-11-2621342823922396498Search in Google Scholar

30 Berindan-Neagoe I, Chiorean R, Braicu C, Florian IS, Leucuta D, Crisan D, et al. Quantitative mRNA expression of genes involved in angiogenesis, coagulation and inflammation in multiforme glioblastoma tumoral tissue versus peritumoral brain tissue: lack of correlation with clinical data. Eur Cytokine Netw 2012; 23: 45-55. 10.1684/ecn.2012.030222591734Search in Google Scholar

31 Stark AM, Doukas A, Hugo H-H, Mehdorn HM. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res 2010; 32: 816-20. 10.1179/016164110X1264501351505220223108Search in Google Scholar

32 Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, et al. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res 2008; 60: 40-9. 10.1016/j.neures.2007.09.00917980449Search in Google Scholar

33 Liumbruno G , D’Alessandro A, Grazzini G, Zolla L. Blood-related proteomics. J Proteomics 2010; 73: 483-507. 10.1016/j.jprot.2009.06.01019567275Search in Google Scholar

34 Tu C, Rudnick PA, Martinez MY, Cheek KL, Stein SE, Slebos RJC, et al. Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 2010; 9: 4982-91. 10.1021/pr100646w294864120677825Search in Google Scholar

35 Echan LA, Tang H-Y, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005; 5: 3292-303. 10.1002/pmic.20040122816052620Search in Google Scholar

36 Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A, et al. GD₃ synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res 2010; 8: 1526-35. 10.1158/1541-7786.MCR-10-030220889649Search in Google Scholar

37 Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004; 101: 6062-7. 10.1073/pnas.040078210139592315075390Search in Google Scholar

38 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. 10.1016/j.cell.2011.02.01321376230Search in Google Scholar

39 Nabika S, Kiya K, Satoh H, Mizoue T, Kondo H, Katagiri M, et al. Prognostic significance of expression patterns of EGFR family, p21 and p27 in highgrade astrocytoma. Hiroshima J Med Sci 2010; 59: 65-70. Search in Google Scholar

40 Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009; 65: 153-9; discussion 159-60. 10.1227/01.NEU.0000348550.47441.4B19574837Search in Google Scholar

41 Correia RL, Oba-Shinjo SM, Uno M, Huang N, Marie SKN. Mitochondrial DNA depletion and its correlation with TFAM, TFB1M, TFB2M and POLG in human diffusely infiltrating astrocytomas. Mitochondrion 2011; 11: 48-53. 10.1016/j.mito.2010.07.00120643228Search in Google Scholar

42 Hagedorn M, Delugin M, Abraldes I, Allain N, Belaud-Rotureau M-A, Turmo M, et al. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div 2007; 2: 9. 10.1186/1747-1028-2-9181937817326833Search in Google Scholar

43 Liu X, Valentine SJ, Plasencia MD, Trimpin S, Naylor S, Clemmer DE. Mapping the human plasma proteome by SCX-LC-IMS-MS. J Am Soc Mass Spectrom 2007; 18: 1249-64. 10.1016/j.jasms.2007.04.012219576717553692Search in Google Scholar

44 Nakamura K, Kodera H, Akita T, Shiina M, Kato M, Hoshino H, et al. De Novo mutations in GNAO1, encoding a Gαo subunit of heterotrimeric G proteins, cause epileptic encephalopathy. Am J Hum Genet 2013; 93: 496-505. 10.1016/j.ajhg.2013.07.014376991923993195Search in Google Scholar

45 Galli C, Meucci O, Scorziello A, Werge TM, Calissano P, Schettini G. Apoptosis in cerebellar granule cells is blocked by high KCl, forskolin, and IGF-1 through distinct mechanisms of action: the involvement of intracellular calcium and RNA synthesis. J Neurosci 1995; 15: 1172-9. 10.1523/JNEUROSCI.15-02-01172.1995Search in Google Scholar

46 Valerie NCK, Dziegielewska B, Hosing AS, Augustin E, Gray LS, Brautigan DL, et al. Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells. Biochem Pharmacol 2013; 85: 888-97. 10.1016/j.bcp.2012.12.01723287412Search in Google Scholar

47 Liu Z, Zhang J, Wu L, Liu J, Zhang M. Overexpression of GNAO1 correlates with poor prognosis in patients with gastric cancer and plays a role in gastric cancer cell proliferation and apoptosis. Int J Mol Med 2014; 33: 589-96. 10.3892/ijmm.2013.159824366063Search in Google Scholar

48 Pei X, Zhang J, Wu L, Lü B, Zhang X, Yang D, et al. The down-regulation of GNAO1 and its promoting role in hepatocellular carcinoma. Biosci Rep 2013; 33: e00069. 10.1042/BSR20130001377551123984917Search in Google Scholar